drug · small molecule
SINEMET CR
updated 3mo agoby $OGN Organon & Co.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval302 co-mentions · 126 sources
- tagSmall Molecule143 co-mentions · 118 sources
- drugSINEMET108 co-mentions · 84 sources
- drugStalevo19 co-mentions · 19 sources
- drugSTALEVO 7519 co-mentions · 19 sources
- druglevodopa CR12 co-mentions · 3 sources
- druglevodopa12 co-mentions · 3 sources
- drugINBRIJA12 co-mentions · 3 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.
targets
Aromatic-L-amino-acid decarboxylase
all catalysts(0)
nothing on the calendar yet
Trials studying SINEMET CR
- phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
- phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
- —Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
- phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
- phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
- phase2Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
- phase1A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
- phase2Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia
News(2)
- BioVie shares halve on murky Parkinson’s disease readoutBioVie’s stock fell by nearly 50% as the biotech claimed victory in a mid-stage Parkinson’s disease trial using an alternative endpoint to the primary clinical goal.biospace · 5d ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 11d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that